Table 1 Baseline characteristics of the study patients before and after propensity-score matched cohorts.
Characteristics | Overall cohort | Matched cohort | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
APD (n = 2,346) | CAPD (n = 7,175) | p-value | APD (n = 2,287) | CAPD (n = 2,287) | p-value | |||||
Gender: men | 1,224 | (52.2) | 3,183 | (44.4) | <0.001 | 1,181 | (51.6) | 1,181 | (51.6) | 1.00 |
Age at cohort entry | 53.6 | [16.2] | 53.5 | [14.8] | 0.81 | 53.8 | [6.1] | 53.9 | [6.1] | 0.89 |
<30 | 195 | (8.3) | 458 | (6.4) | 181 | (7.9) | 181 | (7.9) | 1.00 | |
30–39 | 330 | (14.1) | 857 | (11.9) | 308 | (13.5) | 308 | (13.5) | ||
40–49 | 446 | (19.0) | 1613 | (22.5) | 445 | (19.5) | 445 | (19.5) | ||
50–59 | 533 | (22.7) | 1907 | (26.6) | 529 | (22.9) | 529 | (22.9) | ||
60–69 | 426 | (18.2) | 1290 | (18.0) | 412 | (18.0) | 412 | (18.0) | ||
≥70 | 416 | (17.7) | 1050 | (14.6) | 412 | (18.0) | 412 | (18.0) | ||
Year at cohort entry | <0.001 | 1.00 | ||||||||
2001 | 73 | (3.1) | 569 | (7.9) | 73 | (3.2) | 73 | (3.2) | ||
2002 | 81 | (3.5) | 529 | (7.4) | 81 | (3.5) | 81 | (3.5) | ||
2003 | 123 | (5.2) | 597 | (8.3) | 120 | (5.3) | 120 | (5.3) | ||
2004 | 126 | (5.4) | 626 | (8.7) | 126 | (5.5) | 126 | (5.5) | ||
2005 | 142 | (6.1) | 649 | (9.1) | 138 | (6.0) | 138 | (6.0) | ||
2006 | 184 | (7.8) | 752 | (10.5) | 181 | (7.9) | 181 | (7.9) | ||
2007 | 290 | (12.4) | 947 | (13.2) | 289 | (12.6) | 289 | (12.6) | ||
2008 | 386 | (16.5) | 895 | (12.5) | 379 | (16.6 | 379 | (16.6 | ||
2009 | 476 | (20.3) | 802 | (11.2) | 453 | (19.8) | 453 | (19.8) | ||
2010 | 465 | (19.8) | 809 | (11.3) | 447 | (19.6) | 447 | (19.6) | ||
Charlson comorbid index * | 3.95 | [1.88] | 3.75 | [1.91] | <0.001 | 3.94 | [1.87] | 3.85 | [1.94] | 0.08 |
No. of hospitalizations † | 2.48 | [1.90] | 2.31 | [1.91] | <0.001 | 2.47 | [1.89] | 2.39 | [2.07] | 0.20 |
Comorbidities, (ICD-9-CM codes) † | ||||||||||
Diabetes mellitus (250) | 992 | (42.3) | 2658 | (37.0) | <0.001 | 967 | (42.3) | 945 | (41.3) | 0.51 |
Hypertension (401–405) | 2,096 | (89.3) | 6,104 | (85.1) | <0.001 | 2,045 | (89.4) | 2,035 | (89.0) | 0.63 |
Cancer (140–208) | 98 | (4.2) | 309 | (4.3) | 0.79 | 97 | (4.2) | 109 | (4.8) | 0.39 |
COPD (491–493, 495–496) | 152 | (6.5) | 438 | (6.1) | 0.51 | 149 | (6.5) | 123 | (5.4) | 0.10 |
Gastric ulcer (531–534) | 465 | (19.8) | 1287 | (17.9) | 0.04 | 451 | (19.7) | 402 | (17.6) | 0.06 |
Cirrhosis of liver (571) | 151 | (6.4) | 520 | (7.3) | 0.18 | 145 | (6.3) | 181 | (7.9) | 0.04 |
Dementia (290) | 15 | (0.6) | 65 | (0.9) | 0.22 | 13 | (0.6) | 19 | (0.8) | 0.29 |
Cerebrovascular disease (430–438) | 237 | (10.1) | 636 | (8.9) | 0.07 | 230 | (10.1 | 198 | (8.7) | 0.10 |
Peripheral vascular disease (440.2, 443) | 31 | (1.3) | 107 | (1.5) | 0.55 | 31 | (1.4) | 31 | (1.4) | 1.00 |
Cardiac dysrhythmia (426, 427) | 152 | (6.5) | 445 | (6.2) | 0.63 | 148 | (6.5) | 118 | (5.2) | 0.06 |
Ischemic heart disease (411, 413, 414) | 477 | (20.3) | 1387 | (19.3) | 0.29 | 467 | (20.4) | 418 | (18.3) | 0.07 |
Myocardial infarction (410, 412) | 66 | (2.8) | 187 | (2.6) | 0.59 | 73 | (3.2) | 54 | (2.4) | 0.09 |
Chronic heart failure (428) | 408 | (17.4) | 1086 | (15.1) | <0.01 | 394 | (17.2) | 373 | (16.3) | 0.41 |
Medications at cohort entry ‡ | ||||||||||
Anti-hypertension agents | 2,254 | (96.1) | 6,784 | (94.6) | <0.01 | 2,199 | (96.2) | 2,196 | (96.0) | 0.82 |
Anti-platelet agents | 655 | (27.9) | 2128 | (29.7) | 0.11 | 640 | (28.0) | 633 | (27.7) | 0.82 |
Lipid-lowering agents | 592 | (25.2) | 1531 | (21.3) | <0.001 | 566 | (24.8) | 569 | (24.9) | 0.92 |
Oral hypoglycemic agents or insulins | 961 | (41.0) | 2551 | (35.6) | <0.001 | 937 | (41.0) | 921 | (40.3) | 0.63 |
Premium wage classes | <0.001 | 0.06 | ||||||||
Class 1 ≤ USD 760 | 237 | (10.1) | 743 | (10.4) | 231 | (10.1) | 231 | (10.1) | ||
Class 1 USD 761–1,210 | 243 | (10.4) | 645 | (9.0) | 233 | (10.2) | 207 | (9.1) | ||
Class 1 USD 1,201–1,927 | 308 | (13.1) | 805 | (11.2) | 289 | (12.6) | 246 | (10.8) | ||
Class 1 > USD 1,927 | 224 | (9.6) | 570 | (7.9) | 213 | (9.3) | 171 | (7.5) | ||
Class 2-class 6 | 1334 | (56.9) | 4412 | (61.5) | 1321 | (57.8) | 1432 | (62.6) | ||
